1. Home
  2. LANV vs GBIO Comparison

LANV vs GBIO Comparison

Compare LANV & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lanvin Group Holdings Limited

LANV

Lanvin Group Holdings Limited

HOLD

Current Price

$1.75

Market Cap

228.0M

Sector

Finance

ML Signal

HOLD

Logo Generation Bio Co.

GBIO

Generation Bio Co.

HOLD

Current Price

$5.49

Market Cap

36.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LANV
GBIO
Founded
2015
2016
Country
China
United States
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
228.0M
36.3M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
LANV
GBIO
Price
$1.75
$5.49
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$8.88
AVG Volume (30 Days)
45.6K
61.5K
Earning Date
08-29-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$341,783,911.00
$15,270,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$6.90
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.38
$3.00
52 Week High
$2.69
$12.50

Technical Indicators

Market Signals
Indicator
LANV
GBIO
Relative Strength Index (RSI) 39.47 53.96
Support Level $1.42 $5.20
Resistance Level $2.30 $5.54
Average True Range (ATR) 0.19 0.24
MACD -0.04 0.04
Stochastic Oscillator 37.50 66.67

Price Performance

Historical Comparison
LANV
GBIO

About LANV Lanvin Group Holdings Limited

Lanvin Group Holdings Ltd engages in offering products ranging from apparel to leather goods, footwear, and accessories. The firm is operating mainly 5 portfolio brands, namely Lanvin, Wolford, Sergio Rossi, St. John, and Caruso. It derives the majority of its revenue from the Wolford segment.

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

Share on Social Networks: